Patrick Forde: Happy to Present Advanced NSCLC Study Results at ENA26
Patrick Forde/Facebook

Patrick Forde: Happy to Present Advanced NSCLC Study Results at ENA26

Patrick Forde, Professor at The Johns Hopkins University, shared on X:

“Enjoyed presenting the results of the BioNTech mRNA TAA Fixvac phase 1 trial, BNT116 +/- cemiplimab in advanced NSCLC at ENA26. Efficacy signals in 1st line frail patients and post prior PD1, ongoing cohorts including oncogene-driven tumors.”

See important takeaways from the presentation in the gallery.

You can also read:

BioNTech Shares Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy in Metastatic HPV16-Positive HNC
Patrick Forde: Happy to Present Advanced NSCLC Study Results at ENA26

Other articles about ENA 2026 on OncoDaily.